Larsen AT, Mohamed KE, Sonne N, Bredtoft E, Andersen F, Karsdal MA, et al
The peptide has not received approval from Health Canada for therapeutic use in humans
Retatrutide may become the high-efficacy benchmark if Phase 3 and regulatory review support the early signal
The CUD participants were recruited in this ancillary study from a wider sample of treatment-seeking patients participating in the Brainswitch project, a double-blind, sham-controlled trial testing the ability of repetitive transcranial magnetic stimulation to treat CUD (preliminary data published in Martinotti et al
For more information or media inquiries, email [email protected].
This site in the dorsogluteal muscle is difficult to use for self-injection and is not recommended